Drug Profile
AVP 13358
Alternative Names: Anti-IgE agents - AvanirLatest Information Update: 17 Mar 2017
Price :
$50
*
At a glance
- Originator Avanir Pharmaceuticals
- Class Antiallergics; Antiasthmatics; Benzimidazoles; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis
Most Recent Events
- 26 Apr 2005 Data presented at the 61st Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2005) have been added to the Obstructive Airways Disease pharmacodynamics section
- 15 Feb 2005 This compound is still in active development
- 07 May 2004 Clinical data from a media release have been added to the pharmacokinetics section